Women with psoriatic arthritis (PsA) experience higher disease activity during the perimenopause transition compared with the ...
Osteoarthritis is the most common joint disease worldwide. How to prevent it and why surgery should be the last ...
New long‑term clinical data show that TREMFYA® (guselkumab), an IL‑23 inhibitor, is the first treatment of its kind to ...
What lies beneath the surface? Ultrasound is revealing the earliest signs of psoriatic arthritis, and changing care in the ...
Johnson & Johnson (J&J) has announced new data showing that Tremfya (guselkumab) reduces symptoms of psoriatic arthritis (PsA ...